ARUP's Laboratory Test Directory
| 0050904: Neuronal Nuclear Antibody (ANNA) IgG by IFA with Reflex to Titer & Immunoblot, Serum |
| Test Mnemonic: ANNAR | |
|
Methodology: Indirect Fluorescent Antibody/Immunoblot
Performed: Wed Reported: 1-9 days |
| Specimen Required: | |
|
Collect: One 4 mL SST.
Transport: 1 mL serum, frozen. (Min: 0.5 mL) Submit specimen in an ARUP Standard Transport Tube. Pediatric Collection/Transport: 0.15 mL serum, frozen. Remarks: Separate serum from cells ASAP. Unacceptable Conditions: Plasma. Severely lipemic, contaminated, heat-inactivated, or hemolyzed specimens. Stability: After separation from cells: Ambient: 24 hours; Refrigerated: 5 days; Frozen: 1 year |
|
| Reference Interval: | |||||||||||||||||||||
|
| Interpretive Data: | |
|
ANNA-1 (anti-Hu) and ANNA-2 (anti-Ri) are screened by immunofluorescence and confirmed by immunoblot detection of antibody reactive with a 35-40 kDa (ANNA-1) or a 55 kDa (ANNA-2) neuronal protein. ANNA-1 is present in patients with paraneoplastic syndromes (paraneoplastic sensory neuropathy or paraneoplastic encephalomyelitis) most commonly associated with small-cell lung carcinoma (SCLC). ANNA-2 is present in patients with midbrain encephalitis, cerebellar ataxia, eye movement disorders (usually opsoclonus), and occasionally myelopathy. Neoplasms most often associated with ANNA-2 are breast carcinoma and SCLC. ANNA-1 and ANNA-2 may be detectable before the associated neoplasm is detectable. ANNA antibodies are screened by IFA. If the IFA screen shows reactivity at 1:10, the sample will be titered to endpoint and confirmed (Hu or Ri) by immunoblot. Please refer to Statement D in the Compliance Statements section in the front of the Laboratory Test Directory. |
| Note: | |
| ANNA antibodies are screened by IFA. If the IFA screen is 1:10, then a titer and immunoblot (Hu and Ri) will be added. |
| CPT Code(s): | |
| 86255 ANNA; if reflexed, add 86256 ANNA titer and 83516 Immunoblot |